var data={"title":"Alprostadil: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Alprostadil: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5594?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=alprostadil-patient-drug-information\" class=\"drug drug_patient\">see &quot;Alprostadil: Patient drug information&quot;</a> and <a href=\"topic.htm?path=alprostadil-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Alprostadil: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708622\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Apnea (Prostin VR Pediatric): </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Apnea is experienced by about 10% to 12% of neonates with congenital heart defects treated with alprostadil pediatric sterile solution. Apnea is most often seen in neonates weighing less than 2 kg at birth and usually appears during the first hour of drug infusion. Therefore, monitor respiratory status throughout treatment, and use alprostadil pediatric injection where ventilatory assistance is immediately available.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132167\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Caverject;</li>\n      <li>Caverject Impulse;</li>\n      <li>Edex;</li>\n      <li>Muse;</li>\n      <li>Prostin VR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132168\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Alprostadil Injection USP;</li>\n      <li>Caverject;</li>\n      <li>Muse Pellet;</li>\n      <li>Prostin VR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132207\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Prostaglandin;</li>\n      <li>\n        Vasodilator</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132171\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Erectile dysfunction:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Intracavernous (Caverject, Caverject Impulse, Edex):</i> Individualize dose by careful titration; doses &gt;40 mcg (Edex) or &gt;60 mcg (Caverject) are not recommended: Initial dose must be titrated in health care provider setting. Patient must stay in the health care setting until complete detumescence occurs; if there is no response, then the next higher dose may be given within 1 hour; if there is still no response, a 1-day interval before giving the next dose is recommended; increasing the dose or concentration in the treatment of impotence results in increasing pain and discomfort.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial dose titration: According to the prescribing information for Caverject and Caverject Impulse, no more than 2 doses during the initial titration should be given within a 24 hour period.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Vasculogenic, psychogenic, or mixed etiology: Initiate dosage titration at 2.5 mcg.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>If there is a partial response</i>, increase dose by 2.5 mcg to a dose of 5 mcg and then, in increments of 5 to 10 mcg (depending on erectile response) until the dose that produces an erection suitable for intercourse and not exceeding a duration of 1 hour is reached.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>If there is no response</i> to the initial 2.5 mcg dose, the second dose may be increased to 7.5 mcg and administered within 1 hour, followed by increments of 5 to 10 mcg (Edex).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>If there is a response</i>, then there should be at least a 24 hour interval before the next dose is given.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Neurogenic etiology (eg, spinal cord injury): <b>Note:</b> Caverject powder must be used to prepare a 1.25 mcg dose: Initiate dosage titration at 1.25 mcg; if there's a partial response, may increase to a dose of 2.5 mcg within 1 hour and if necessary, to a dose of 5 mcg; may increase further in increments of 5 mcg until the dose is reached that produces an erection suitable for intercourse, not lasting &gt;1 hour.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance: Once an appropriate dose has been determined, patient may self-administer injections at a frequency of no more than 3 times/week with at least 24 hours between doses</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Intraurethral (Muse Pellet): </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial: 125 to 250 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance: Administer as needed to achieve an erection; duration of action is about 30 to 60 minutes; use only two systems per 24-hour period</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Raynaud phenomenon (off-labeled use): </b>IV: 60 mcg over 3 hours once daily for 5 consecutive days (loading dose) followed by maintenance dosing of 60 mcg over 3 hours once every 30 days for 2 doses (Marasini 2004) <b>or </b> 60 mcg over 3 hours once daily for 6 consecutive days (Bartolone 1999) <b>or</b> 40 mcg (at a rate of 3 to 5 ng/kg/minute) twice daily for a minimum duration of 7 days and repeated every 3 to 4 weeks (Lamprecht 1998)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132189\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=alprostadil-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Alprostadil: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patent ductus arteriosus</b> IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Prostin VR Pediatric:</i> IV continuous infusion into a large vein, or alternatively through an umbilical artery catheter placed at the ductal opening: 0.05-0.1 mcg/kg/minute with therapeutic response, rate is reduced to lowest effective dosage. With unsatisfactory response, rate is increased gradually; maintenance: 0.01-0.4 mcg/kg/minute. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Note:</b> Alprostadil is usually given at an infusion rate of 0.1 mcg/kg/minute, but it is often possible to reduce the dosage to <sup>1</sup>/<sub>2</sub> or even <sup>1</sup>/<sub>10</sub> without losing the therapeutic effect.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Note:</b> Therapeutic response is indicated by increased pH in those with acidosis or by an increase in oxygenation (PO<sub>2</sub>) usually evident within 30 minutes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132172\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Use lowest effective dose. In clinical studies with Edex, higher minimally effective doses and a higher rate of lack of effect were noted. Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15671405\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15671406\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132144\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Intracavernosal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Caverject Impulse: 10 mcg [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Caverject Impulse: 20 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Edex: 10 mcg, 20 mcg, 40 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pellet, Urethral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Muse: 125 mcg (1 ea, 6 ea); 250 mcg (1 ea, 6 ea); 500 mcg (1 ea, 6 ea); 1000 mcg (1 ea, 6 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prostin VR: 500 mcg/mL (1 mL) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mcg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intracavernosal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Caverject: 20 mcg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Caverject: 20 mcg (1 ea); 40 mcg (1 ea) [contains benzyl alcohol]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132129\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132147\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Patent ductus arteriosus (Prostin VR Pediatric): IV continuous infusion into a large vein or alternatively through an umbilical artery catheter placed at the ductal opening; manufacturer recommended maximum concentration for IV infusion: 20 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intracavernous: Erectile dysfunction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Caverject:</i> Use a <sup>1</sup>/<sub>2</sub> inch, 29- or 30-gauge needle. Inject into the dorsolateral aspect of the proximal third of the penis, avoiding visible veins; alternate side of the penis for injections. Compress the site of injection with an alcohol swab or sterile gauze for 5 minutes after administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Caverject Impulse:</i> Supplied as a disposable, single-dose, dual chamber syringe system. After attaching the provided needle assembly, select dose and inject into the dorsolateral aspect of the proximal third of the penis, avoiding visible veins; alternate side of the penis for injections. Compress the site of injection with an alcohol swab or sterile gauze for 5 minutes after administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Edex:</i> Use a <sup>1</sup>/<sub>2</sub> inch, 27- to 30-gauge needle. Inject into the dorsolateral aspect of the proximal third of the penis, avoiding visible veins; alternate side of the penis for injections. Administer over a 5- to 10-second interval. Compress the site of injection with an alcohol swab for 5 minutes after administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471275\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 10 mcg/mL <b>or</b> 20 mcg/mL </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132146\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patent ductus arteriosus (Prostin VR Pediatric):</b> Temporary maintenance of patency of ductus arteriosus in neonates with ductal-dependent congenital heart disease until surgery can be performed. These defects include cyanotic (eg, pulmonary atresia, pulmonary stenosis, tricuspid atresia, Fallot's tetralogy, transposition of the great vessels) and acyanotic (eg, interruption of aortic arch, coarctation of aorta, hypoplastic left ventricle) heart disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Erectile dysfunction:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Caverject, Edex, Caverject Impulse:</b> Treatment of erectile dysfunction due to vasculogenic, psychogenic, neurogenic, or mixed etiology; Caverject may be a useful adjunct to other diagnostic tests in the diagnosis of erectile dysfunction </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Muse:</b> Treatment of erectile dysfunction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25720652\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Pulmonary hypertension in patients with congenital heart defects and left-to-right shunts (infants/children/adolescents); Raynaud phenomenon</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132214\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Alprostadil may be confused with alPRAZolam</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Prostin VR may be confused with Prostin E2 (dinoprostone)</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132136\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intraurethral:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;10%: Genitourinary: Penile pain, urethral burning</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">2% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Dizziness, headache, pain</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Genitourinary: Testicular pain, urethral bleeding (minor), vulvovaginal pruritus (female partner)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;2%: Leg pain, perineal pain, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intracavernosal injection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;10%: Genitourinary: Penile pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardiovascular: Hypertension</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Dizziness, headache</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Genitourinary: Prolonged erection (&gt;4 hours, 4%), penile disease, penile rash, penile swelling, Peyronie's disease</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Local: Bruising at injection site, hematoma at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;1%: Balanitis, injection site hemorrhage, priapism (0.4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intravenous:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardiovascular: Flushing</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Respiratory: Apnea</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardiovascular: Bradycardia, cardiac arrest, edema, hypertension, hypotension, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Dizziness, headache, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endocrine &amp; metabolic: Hypokalemia</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrointestinal: Diarrhea</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hematologic &amp; oncologic: Disseminated intravascular coagulation</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infection: Sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Local: Local pain (in structures other than the injection site)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neuromuscular &amp; skeletal: Back pain</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Respiratory: Cough, flu-like symptoms, nasal congestion, sinusitis, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;1%: Anemia, anuria, bradypnea, cardiac failure, cerebral hemorrhage, gastroesophageal reflux disease, hematuria, hemorrhage, hyperbilirubinemia, hyperemia, hyperirritability, hyperkalemia, hypoglycemia, hypothermia, jitteriness, lethargy, neck hyperextension, peritonitis, second degree atrioventricular block, shock, stiffness, supraventricular tachycardia, thrombocytopenia, ventricular fibrillation, wheezing (bronchial)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132150\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intracavernous: Hypersensitivity to alprostadil or any component of the formulation; conditions predisposing men to priapism (eg, sickle cell anemia or trait, multiple myeloma, leukemia); men with anatomical deformation or fibrotic conditions of the penis (eg, angulation, cavernosal fibrosis, or Peyronie disease); penile implants</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: There are no contraindications listed in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transurethral: Hypersensitivity to alprostadil or any component of the formulation; urethral stricture, balanitis, severe hypospadias and curvature, and in men with acute or chronic urethritis; men who are prone to venous thrombosis or who have a hyperviscosity syndrome (eg, sickle cell anemia or trait, thrombocythemia, polycythemia, multiple myeloma) predisposing them to priapism; use in men for whom sexual activity is inadvisable; sexual intercourse with a pregnant woman unless a condom barrier is being used</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Documentation of allergenic cross-reactivity for prostaglandins is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132133\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Apnea: <b>[US Boxed Warning]: Prostin VR Pediatric: Apnea may occur in 10% to 12% of neonates with congenital heart defects, especially in those weighing &lt;2 kg at birth.</b> Apnea usually appears during the first hour of drug infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension/syncope: Intracavernous injections can increase peripheral blood levels of alprostadil, resulting in hypotension. Syncope has also been reported. Avoid use in men with known cavernosal venous leakage. Patients must be cautioned to avoid tasks such as operating machinery or driving following administration where injury could result if hypotension or syncope were to occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Penile fibrosis: May occur when used for erectile dysfunction; discontinue use in men who develop penile angulation or cavernosal fibrosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Priapism/prolonged erection: May occur when used for erectile dysfunction; instruct patient to seek immediate medical assistance if an erection persists &ge;4 hours; discontinue therapy if priapism or prolonged erection occurs or if signs of penile fibrosis develop (penile angulation, cavernosal fibrosis, or Peyronie disease). To minimize the chances of prolonged erection or priapism, titrate slowly to the lowest effective dose. Use is contraindicated in men who have conditions that predispose them to priapism (eg, sickle cell anemia or trait, multiple myeloma, leukemia). Underlying causes of erectile dysfunction should be evaluated and treated prior to therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Treatment for erectile dysfunction should not be used in men whom sexual activity is inadvisable because of underlying cardiovascular status.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neonates: Prostin VR Pediatric: Use with caution in neonates with bleeding tendencies.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: Muse: Urethral abrasion resulting in minor bleeding or spotting may occur from improper administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Needle breakage: Caverject and Caverject Impulse: A superfine needle is used for administration. Needle breakage (a portion of the needle remaining in the penis) has been reported; hospitalization and surgical removal may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patency of ductus arteriosus: Appropriate use: Prostin VR Pediatric: Infuse for the shortest time at the lowest dose consistent with good patient care. Use for &gt;120 hours has been associated with antral hyperplasia and gastric outlet obstruction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298715\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132138\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8459&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the adverse/toxic effect of Alprostadil.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132140\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (Muse) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132153\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Alprostadil is not indicated for use in women. The manufacturer of Muse recommends a condom barrier when being used during sexual intercourse with a pregnant woman. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20520330\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Alprostadil is not indicated for use in women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132142\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure, respiratory rate, heart rate, temperature, degree of penile pain, duration of erection, adequate detumescence after dosing, signs of infection </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132132\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Causes vasodilation by means of direct effect on vascular and ductus arteriosus smooth muscle; relaxes trabecular smooth muscle by dilation of cavernosal arteries when injected along the penile shaft, allowing blood flow to and entrapment in the lacunar spaces of the penis (ie, corporeal veno-occlusive mechanism)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132149\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Erectile dysfunction: 5 to 20 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Ductus arteriosus will begin to close within 1 to 2 hours after drug is stopped; Erectile dysfunction: Intended duration &lt;1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Insignificant following penile injection </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding, plasma: 81% to albumin </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: IV: ~70% to 80% by oxidation during a single pass through the lungs; metabolite (13,14 dihydro-PGE<sub>1</sub>) is active and has been identified in neonates </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 30 seconds to 10 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Acyanotic congenital heart disease: Usual: 1.5 to 3 hours; Range: 15 minutes to 11 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cyanotic congenital heart disease: Usual: ~30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Erectile dysfunction: Intracavernosal 30 to 60 minutes; Transurethral: ~16 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Primarily urine (90% as metabolites) within 24 hours; feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132152\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Caverject Impulse Intracavernosal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mcg (1): $92.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mcg (1): $119.11</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Edex Intracavernosal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mcg (1): $144.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mcg (1): $186.35</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mcg (1): $254.48</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pellet</b> (Muse Urethral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mcg (1): $70.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mcg (1): $74.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mcg (1): $79.38</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mcg (1): $85.73</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Alprostadil Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mcg/mL (1 mL): $130.01</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Prostin VR Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mcg/mL (1 mL): $142.28</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Caverject Intracavernosal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mcg (1): $118.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mcg (1): $155.90</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132154\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alostin (KR);</li>\n      <li>Alprostan (RU, UA);</li>\n      <li>Alprostapint (BG, HU, VN);</li>\n      <li>Caverject (AE, AR, AT, BB, BH, BM, BO, BR, BS, BZ, CL, CO, CR, CY, DE, DO, EC, EE, EG, ES, FR, GB, GT, GY, HU, IE, IQ, IR, IS, JM, JO, KR, KW, LB, LU, LV, LY, MX, MY, NI, NL, NO, NZ, OM, PA, PE, PR, PT, PY, QA, SA, SE, SG, SI, SR, SV, SY, TR, TT, TW, UY, VE, VN, YE, ZA);</li>\n      <li>Caverject Dual Chamber (FR, HK);</li>\n      <li>Caverject Impulse (AU);</li>\n      <li>Caverjet (IL);</li>\n      <li>Edex (FR);</li>\n      <li>Eglandin (KR);</li>\n      <li>Gaverject (PK);</li>\n      <li>Liple (JP);</li>\n      <li>Minprog (AT);</li>\n      <li>Muse (AE, BH, CY, EG, ES, GB, IE, IQ, IR, JO, KW, LB, LT, LV, LY, OM, QA, SA, SY, YE, ZA);</li>\n      <li>Palux (JP);</li>\n      <li>Pridax (RO);</li>\n      <li>Prink (KR);</li>\n      <li>Promostan (TW);</li>\n      <li>Prostandin (JP, KR);</li>\n      <li>Prostavasin (AE, AR, BR, CN, CR, CY, DO, EG, GT, HN, HU, JO, KW, LU, MX, NI, PA, PH, SK, SV, UY);</li>\n      <li>Prostin Pediatrico (CL);</li>\n      <li>Prostin VR (AE, AU, BE, BH, CH, CO, CY, EG, GB, GR, HN, HR, HU, IL, IN, IQ, IR, IT, JO, KW, LB, LU, LY, NL, NZ, OM, PL, QA, SA, SY, TH, TW, YE, ZA);</li>\n      <li>Prostin VR Paedeatric (MY);</li>\n      <li>Prostin VR Pediatric (HK);</li>\n      <li>Prostine VR (FR);</li>\n      <li>Prostivas (DK, FI, NO, SE);</li>\n      <li>Vazostenon (UA);</li>\n      <li>Viridal (DE, IE);</li>\n      <li>Virilan (AT);</li>\n      <li>Vitaros (GB, IE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bartolone S, Trifiletti A, De Nuzzo G, et al. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon. <i>Minerva Cardioangiol</i>. 1999;47(5):137-143.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/10479851/pubmed\" target=\"_blank\" id=\"10479851\">10479851</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Caverject (alprostadil) [prescribing information]. New York, NY: Pfizer Inc; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Caverject Impulse (alprostadil) [prescribing information]. New York, NY: Pfizer Inc; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol-United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo; <i>Am J Health-Syst Pharm</i>, 2007, 64(16):1711-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/17687059/pubmed\" target=\"_blank\" id=\"17687059\">17687059</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Edex (alprostadil) [prescribing information]. Lake Forest, IL: Actient Pharmaceuticals; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practice (ISMP) and Vermont Oxford Network, &ldquo;Standard Concentrations of Neonatal Drug Infusions,&rdquo; 2011. Available at https://www.ismp.org/Tools/PediatricConcentrations.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lamprecht P, Schnabel A, Gross WL. Efficacy of alprostadil and iloprost in digital necrosis due to secondary Raynaud's phenomenon. <i>Br J Rheumatol</i>. 1998;37(6):703-704.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/9667634/pubmed\" target=\"_blank\" id=\"9667634\">9667634</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marasini B, Massarotti M, Bottasso B, et al. Comparison between iloprost and alprostadil in the treatment of Raynaud's phenomenon. <i>Scand J Rheumatol</i>. 2004;33(4):253-256.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/15370722/pubmed\" target=\"_blank\" id=\"15370722\">15370722</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Muse (alprostadil) [prescribing information]. Somerset, NJ: Meda Pharmaceuticals Inc; August 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peled N, Dagan O, Babyn P, et al, &ldquo;Gastric-Outlet Obstruction Induced by Prostaglandin Therapy in Neonates,&rdquo; <i>N Engl J Med</i>, 1992, 327(8):505-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/1635565/pubmed\" target=\"_blank\" id=\"1635565\">1635565</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips MS, &ldquo;Standardizing I.V. Infusion Concentrations: National Survey Results,&rdquo; <i>Am J Health Syst Pharm</i>, 2011, 68(22):2176-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/22058104/pubmed\" target=\"_blank\" id=\"22058104\">22058104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prostin VR Pediatric (alprostadil injection) [prescribing information]. New York, NY: Pfizer Injectables; April 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"1913785\"></a>Weesner KM, &ldquo;Hemodynamic Effects of Prostaglandin E<sub>1</sub> in Patients With Congenital Heart Disease and Pulmonary Hypertension,&rdquo; <i>Cathet Cardiovasc Diagn</i>, 1991, 24(1):10-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/1913785/pubmed\" target=\"_blank\" id=\"1913785\">1913785</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Williams G, Abbou CC, Amar ET, et al, &ldquo;The Effect of Transurethral Alprostadil on the Quality of Life of Men With Erectile Dysfunction, and Their Partners. MUSE Study Group,&rdquo; <i>Br J Urol</i>, 1998, 82(6):847-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/9883223/pubmed\" target=\"_blank\" id=\"9883223\">9883223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Woo K, Emery J, and Peabody J, &ldquo;Cortical Hyperostosis: A Complication of Prolonged Prostaglandin Infusion in Infants Awaiting Cardiac Transplantation,&rdquo; <i>Pediatrics</i>, 1994, 93(3):417-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alprostadil-drug-information/abstract-text/8115200/pubmed\" target=\"_blank\" id=\"8115200\">8115200</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8459 Version 148.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708622\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F132167\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F132168\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F132207\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F132171\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F132189\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F132172\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15671405\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15671406\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F132144\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F132129\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F132147\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14471275\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F132146\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25720652\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F132214\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F132136\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F132150\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F132133\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298715\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F132138\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F132140\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F132153\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20520330\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F132142\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F132132\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F132149\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F132152\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F132154\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8459|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=alprostadil-patient-drug-information\" class=\"drug drug_patient\">Alprostadil: Patient drug information</a></li><li><a href=\"topic.htm?path=alprostadil-pediatric-drug-information\" class=\"drug drug_pediatric\">Alprostadil: Pediatric drug information</a></li></ul></div></div>","javascript":null}